Wu Jiayun, Li Lingling, Li Lin, Li Yanjun, Xiao Xiang, Qiao Jiajun, Sun Rui, Yang Deshuang, Yao Ruiqi, Huang Li
Beijing University of Chinese Medicine, Beijing 100029, China.
Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing 100029, China.
Evid Based Complement Alternat Med. 2020 Dec 9;2020:8856943. doi: 10.1155/2020/8856943. eCollection 2020.
SangQiQingXuan (SQQX) decoction is a pharmaceutical preparation exerting good therapeutic efficacy on high blood pressure (BP) and has widely been accepted in primarily hypertensive patients as a herbal formula prescribed by Professor Li Huang from China-Japan Friendship Hospital according to her 30-year clinical experience. A previous study showed that SQQX could reduce BP by decreasing levels of many inflammatory factors such as transforming growth factor beta (TGF) and elevating peroxisome proliferator activated receptor (PPAR) expression. However, a research focusing on SQQX's protection against HTN from a metabolomic perspective has never been done before. This study aimed to figure out the metabolic profiling variations due to oral administration of SQQX in spontaneous hypertensive rat (SHR) models and to find out the optimal dosage of SQQX. SHR in the intervention group orally received SQQX extract of three doses, namely, the low- (5.25 g/kg/d), middle- (10.5 g/kg/d), and high-dosage groups (21 g/kg/d) for 90 days. Rats were sacrificed at the end of the experiment, and their serum was collected for further examination. Serum metabolic profiling variations were analyzed using ultraperformance liquid chromatography coupled with tandem mass spectrometry (UPLC/MS). Results showed that dealing with SQQX remarkably decreased systolic blood pressure (SBP) of SHRs and the high-dosage group was with the best therapeutic effect where a total of 11 metabolites were markedly changed in contrast to the model group. Orthogonal partial least square discriminant analysis (OPLS-DA) score plot showed that the 5 groups of serum samples were divided into 5 categories, and the metabolic trajectory of the high-dosage SQQX group was inclined to move to the control group. Glycochenodeoxycholic acid, nicotinamide-N-oxide, and tryptophan betaine might be biomarkers that specifically marked the protective effects of SQQX against high BP mainly involving in cholesterol metabolism, primary bile acid biosynthesis, bile secretion, and nicotinate and nicotinamide metabolism. To conclude, SQQX has a protective effect on SHR, which may be partially correlated to restoration of perturbed metabolism in serum.
桑杞清眩(SQQX)汤是一种对高血压具有良好治疗效果的药物制剂,作为中日友好医院李煌教授依据其30年临床经验所开的中药配方,已在原发性高血压患者中广泛应用。先前的一项研究表明,SQQX可通过降低多种炎症因子如转化生长因子β(TGF)的水平及提高过氧化物酶体增殖物激活受体(PPAR)的表达来降低血压。然而,此前从未有过从代谢组学角度研究SQQX对高血压保护作用的报道。本研究旨在明确自发性高血压大鼠(SHR)模型口服SQQX后的代谢谱变化,并找出SQQX的最佳剂量。干预组的SHR分别口服三种剂量的SQQX提取物,即低剂量组(5.25克/千克/天)、中剂量组(10.5克/千克/天)和高剂量组(21克/千克/天),持续90天。实验结束时处死大鼠,收集血清用于进一步检测。采用超高效液相色谱-串联质谱联用技术(UPLC/MS)分析血清代谢谱变化。结果显示,给予SQQX可显著降低SHR的收缩压(SBP),高剂量组治疗效果最佳,与模型组相比共有11种代谢物发生显著变化。正交偏最小二乘判别分析(OPLS-DA)得分图显示,5组血清样本分为5类,高剂量SQQX组的代谢轨迹倾向于向对照组移动。甘氨鹅去氧胆酸、烟酰胺-N-氧化物和色氨酸甜菜碱可能是特异性标记SQQX对高血压保护作用的生物标志物,主要涉及胆固醇代谢、初级胆汁酸生物合成、胆汁分泌以及烟酸和烟酰胺代谢。综上所述,SQQX对SHR具有保护作用,这可能部分与恢复血清中紊乱的代谢有关。